

Table 1: TR02 Mean Reduction in Worst Itch NRS during the Evaluation Period for Patients with Severe UP (NRS \geq 7) (MITT Population)

Mean (SD) NRS Data	NAL 60	NAL 120	Placebo
N (number of patients)	63	61	55
Baseline	N=63 8.05 (0.85)	N=61 8.15 (0.81)	N=55 8.02 (0.89)
Evaluation Period (Observed Cases)	N=44 4.72 (2.74)	N=44 3.73 (2.48)	N=49 4.94 (2.81)
Change from Baseline	-3.44 (2.56)	-4.48 (2.50)	-3.16 (2.65)
LS Mean Difference from Placebo	-0.32	-1.39	
p-value vs Placebo	0.521	0.007*	

*statistical significance defined per protocol as a p-value ≤ 0.05 based step-down analysis specification; initial comparison of NAL 120 vs. placebo based on least square (LS) means